Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) ...

Celltrion, a major South Korean biopharmaceutical firm, said on Tuesday its two new bio-similars for bone disease treatment ...

Celltrion announced Tuesday that its biosimilars Stoboclo and Osenvelt, referencing bone disease treatments Prolia and Xgeva (denosumab), have received marketing approval from the US Food and Drug ...

South Korean biopharmaceutical giant Celltrion announced on Tuesday that its two new biosimilars for bone disease treatment have received approval from the United States Food and Drug Administration ...

SEOUL -- Forty-one ferry sailings and four flights were canceled nationwide Tuesday, anti-disaster authorities said, amid ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

Celltrion’s Remsima surpassed 1 trillion won ($699 million) in sales last year, making it the first drug developed by a ...

South Korean stocks fell for the third consecutive session Tuesday, as US President Donald Trump's sweeping tariff scheme ...

Activist shareholders have been rarely visible ahead of the shareholders' meetings of listed companies later this month, a ...

From left, Cho In-chul, managing director of the passenger vehicle division at BYD Korea, Liu Xueliang, general manager of ...